1. Bellomo R, et al. N Engl J Med. 2009;361(17):1627-1638.
2. Palevsky PM, et al. N Engl J Med. 2008;359(1):7-21.
3. Thompson Bastin ML, et al. Association of Phosphate Containing Solutions with Incident Hypophosphatemia in Critically Ill Patients Requiring Continuous Renal Replacement Therapy. Blood Purif. 2022;51(2):122-129.
Important Safety Information
INDICATIONS
Phoxillum solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.
Important Risk Information:
- Phoxillum replacement solution are contraindicated in patients with known hypersensitivities to these products.
- Phoxillum solution can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure.
- Phoxillum replacement solution contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.
- Phoxillum replacement solution can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly.
- The following adverse reactions have been identified during post-approval use with these or other similar products and therefore may occur with use of Phoxillum or: Metabolic acidosis, hypotension, acid-based disorders, electrolyte imbalances including calcium ionized increased, hyperphosphatemia, hypophosphatemia, fluid imbalance.